The efficacy of thiotropium bromide (Spiriva) in the treatment of patients with chronic obstructive pulmonary disease of varying severity: Results of the Russian trial

Terapevticheskii Arkhiv

Volumn 82, Issue 10, 2010, Pages 46-51

  Stepanyan, I E ^a   Khmelkova, N G ^b   Belin Atarac, B ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b Boehringer Ingelheim Pharma Ges Mbh ^*  (Russian Federation)

Author keywords

Chronic obstructive pulmonary disease; Degree of severity; Postmarketing study; Thiotropium bromide

Indexed keywords

BRONCHODILATING AGENT; SCOPOLAMINE DERIVATIVE; TIOTROPIUM BROMIDE;

ARTICLE; BREATHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MALE; MIDDLE AGED; MULTICENTER STUDY; NEBULIZER; RUSSIAN FEDERATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION; RESPIRATORY FUNCTION TESTS; RUSSIA; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78650047789     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Casabury R., Mahler D., Jones P. et al. A long-term evaluation of oncedaily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.
2. Vincken W., van Noord J. A., Greefhorst A. P. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.
3. Donahue J., van Noord J. A., Bateman E. D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
4. Niewoehner D. E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator, a randomized trial. Ann. Intern. Med. 2005; 143: 317-326.
5. Johansson G., Lindberg A., Romberg K. et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim. Care. Respir. J. 2008; 17: 169-175.
6. Decramer M., Celli B., Tashkin D. P. et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: UPLIFT trial. COPD 2004; 1: 303-312.
7. Tashkin D. P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
8. Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
9. American Thoracic Society. Standartisation of spirometry, 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107-1136.